Patented Medicine Prices Review Board

http://dbpedia.org/resource/Patented_Medicine_Prices_Review_Board an entity of type: Thing

The Patented Medicine Prices Review Board (French: Conseil d'examen du prix des médicaments brevetés) is a federal quasi-judicial regulatory and reporting agency in Canada with a mandate to protect consumers by ensuring that the prices of patented medication charged by manufacturers of patented drugs are not excessive. The board does this through its role as a regulator, and through its reporting on trends, research and development in the Canadian pharmaceutical industry. rdf:langString
rdf:langString Patented Medicine Prices Review Board
rdf:langString Patented Medicine Prices Review Board
xsd:integer 17830047
xsd:integer 1055140932
rdf:langString CA$10.3 million
xsd:integer 74
rdf:langString PMPRB logo.svg
rdf:langString
rdf:langString The Patented Medicine Prices Review Board (French: Conseil d'examen du prix des médicaments brevetés) is a federal quasi-judicial regulatory and reporting agency in Canada with a mandate to protect consumers by ensuring that the prices of patented medication charged by manufacturers of patented drugs are not excessive. The board does this through its role as a regulator, and through its reporting on trends, research and development in the Canadian pharmaceutical industry. The board investigates, reviews and negotiates the price of individual drugs that are still under patent and which have no generic substitutes. It establishes the maximum prices that can be charged in Canada for patented drugs.
rdf:langString Mitchell Levine
rdf:langString Chairperson
rdf:langString Mélanie Bourassa Forcier
rdf:langString Vice-chairperson
rdf:langString Douglas Clark
rdf:langString Executive Director
rdf:langString Patent Act
xsd:nonNegativeInteger 7124
<usDollar> 1.03E7
xsd:gYear 1987
xsd:nonNegativeInteger 74

data from the linked data cloud